EP0523037A4 - Fluid resuscitation - Google Patents

Fluid resuscitation

Info

Publication number
EP0523037A4
EP0523037A4 EP19900907852 EP90907852A EP0523037A4 EP 0523037 A4 EP0523037 A4 EP 0523037A4 EP 19900907852 EP19900907852 EP 19900907852 EP 90907852 A EP90907852 A EP 90907852A EP 0523037 A4 EP0523037 A4 EP 0523037A4
Authority
EP
European Patent Office
Prior art keywords
biopolymer
dfo
fluid resuscitation
deferoxamine
dpo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900907852
Other versions
EP0523037A1 (en
Inventor
Bo Erik Hedlund
Philip E. Hallaway
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomedical Frontiers Inc
Original Assignee
Biomedical Frontiers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Frontiers Inc filed Critical Biomedical Frontiers Inc
Priority claimed from CA002084073A external-priority patent/CA2084073A1/en
Publication of EP0523037A1 publication Critical patent/EP0523037A1/en
Publication of EP0523037A4 publication Critical patent/EP0523037A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Definitions

  • the present invention relates to fluid resuscitation.
  • Such resuscitation is required or is desirable in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived frcm combustion, and hei ⁇ iorrhagic shock.
  • Burn injury is often acco ⁇ panied by injury to the lungs caused by inhalation of hot and/or toxic substances, such as snroke, derived from combustion.
  • the critical period of initial resuscitation i.e. when fluid is administered, is the time when reperfusion injury occurs. During this period, which may be as short as a minute or as long as several hours, oxygen radical mediated injury appears to occur.
  • ej ⁇ anders crystalloids and colloids
  • Deferoxamine or desferrioxamine
  • Deferoxamine mesylate is commercially available and is used to treat severe iron intoxication, iron storage disease or iron overload resulting from hemolysis due to drugs, thalassemia, sickle-cell anemia, frequent blood transfusions and the like.
  • deferoxamine mesylate There are a number of problems with the clinical use of deferoxamine mesylate. Since the drug is not appreciably absorbed when orally administered, it generally must be given parenterally. Once administered, the drug is very rapidly excreted. For example, in humans the drug exhibits a vascular half-life of only about 5-10 min. Chelation therapy with the drug, as a result, involves continuous infusion or frequent intramuscular injections, which may cause pain and/or induration at the injection site. Further, the acute and chronic toxicities of deferoxamine are relatively high, making the substance less versatile for therapeutic uses.
  • DFO deferoxamine
  • DES diethylstilbesterol
  • EP-0 304 183A discloses pharmaceutically acceptable water-soluble biopolymers covalently bonded to deferoxamine. Such biopolymers covalently bonded to deferoxamine are herein referred to as conjugates.
  • Preferred conjugates consist of pharmaceutically acceptable water-soluble polysaccharides covalently bonded to deferoxamine, pharmaceutically acceptable water-soluble proteins covalently bonded to deferoxamine and water-soluble inulm-deferoxamine adducts. It has now been discovered that such conjugates of deferoxamine are useful in fluid resuscitation.
  • the present invention relates to the use of a pharmaceutically acceptable water-soluble biopolymer and deferoxamine (DFO) for use in fluid resuscitation.
  • DFO deferoxamine
  • the invention relates to the use of such biopolymer and DFO for the preparation or manufacture of a medicament for use in fluid resuscitation.
  • the biopolymer may be covalently bonded to the DFO. Conjugation of DFO as described above decreases the toxicity of the DFO whilst not reducing or not proportionally reducing its chelating ability.
  • the biopolymer may be a polysaccharide or a protein.
  • the DPO may be covalently bonded directly to aldehydde groups on the polysaccharide.
  • the DFO may be covalently bonded directly to one or more amino, carboxyl or thiol groups on the protein.
  • the polysaccharide may comprise dextran, hyaluronic acid, inulin, starch, e.g. hydroxyethyl starch or other modified form of starch.
  • the protein may co ⁇ prise serum albumin or other plasma protein fraction (human or animal) or hemoglobin.
  • hemoglobin may be used in resuscitation fluids. Such fluids will provide oxygen to ischemic tissue but may be toxic due to release of iron from the iron-containing protein. The presence of DPO, either bound to or mixed with the hemoglobin may decrease such toxicity.
  • the DFO-conjugate may be prepared by method as described in EP-E- 0 304 183A.
  • DPO and the biopolymer, whether or not conjugated together are preferably formulated as an aqueous solution suitable for parenteral administration e.g. by intramuscular, intraperitoneal or intravenous infusion.
  • the conjugates between, and the simple mixtures of, polysaccharides and DPO preferably contain from 5 to 25% chelator by weight. It is preferred that -solutions having conjugate cor ⁇ _ * entrations between 2 and 10% (w/v) , dissolved in saline or lactated Ringer's solution, are used for fluid resuscitation. Effective doses are generally in the range of from approximately 20 to 300 mg chelator/kg body weight, although higher doses of conjugated DPO can be given in certain circumstances, for example in the treatment of acute iron poisoning. Care should be taken when administering the chelator in a form not conjugated to the colloid, since adverse reactions can occur even at moderate doses. - 4A -
  • Fluid resuscitation using the biopolymer and the DPO ameliorates systemic oxidant injury occurring during ischemia and subsequent reperf sion.
  • the fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke, derived from combustion, - hemorrhagic shock and other types of trauma.
  • Oxygen derived radicals such as the hydroxyl radical
  • Oxygen derived radicals are cytotoxic and highly reactive molecules are thought to contribute to cellular death in hemorrhagic and thermal shock.
  • Production of hydroxyl radical is catalyzed by transition metal ions.
  • Chelation of transition metal ions with DPO prevents formation of hydroxyl radicals.
  • the burn was produced under halothane nitrous anesthesia.
  • the burn involved bilateral prefemoral areas over the distribution of bilateral flanks. Resuscitation was begun immediately post burn. The animals were then monitored for 6 hours, then sacrificed. Three groups of animals were studied.
  • Group 1 Ringers alone as resuscitation fluid Group 2 5% hydroxyethyl starch alone as resuscitation fluid; Group 3 5% deferoxamine chelator attached i.e. (covalently bonded) to hydroxyethyl starch alone as recuscitation fluid.
  • Aortic, . central venous, pulmonary arterial, and pulmonary wedge pressures as well as cardiac output were recorded. Hourly values for arterial and venous blood gases as well as ' co-oximetry were measured. Co-oximetry measurements include total hemoglobin, reduced hemoglobin, oxygen content, oxygen saturation, and oxygen capacity. Dynamic and static lung compliance was also measured. Urine output and specific gravity were recorded.
  • Malondialdehyde (MDA), a measure of lipid peroxidation, was measured in both lung and liver tissue.
  • Group 3 receiving iron chelator atached to hydroxyethyl starch, required significantly less fluid to maintain hemodynamic stability than either of the other two groups.
  • n number of sheep in group.
  • a porcine hemorrhagic shock model was used to evaluate the effects of 3 resuscitative fluids on survival and hepatic function. Fasted swine (14-16 kg) underwent splenectomy and placement cf arterial - 8 -
  • PS pentastarch (a form of hydroxyethyl starch)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to fluid resuscitation of the human or animal body by administration of deferoxamine (DFO) and a water-soluble biopolymer. The DFO and the biopolymer are preferably bonded together. The biopolymer may be a polysaccharide or a protein. The DFO and the biopolymer are preferably formulated as an aqueous solution suitable for oral administration. The fluid resuscitation may be effected for ameliorating systemic oxidant injury occuring during ischemia and subsequent reperfusion. The fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived from combustion, hemorrhagic shock and other types of trauma.

Description

FLUID RESUSCITATION
Field of the Invention
The present invention relates to fluid resuscitation. Such resuscitation is required or is desirable in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke derived frcm combustion, and heiτiorrhagic shock.
Background of the Invention
Thermal injury and severe bleeding lead to shock. The acute therapeutic intervention is similar in both situations: primary treatment is fluid therapy. In the case of hemorrhagic shock, the lost blood volume must be replaced as quickly as possible. Initially lost blood volume is provided either by salt solutions, so called crystalloids, or with colloids, such as dextran or hydroxyethyl starch. If blood is available, the physician will replace lost blood by transfusion.
Burn injury is often accoπpanied by injury to the lungs caused by inhalation of hot and/or toxic substances, such as snroke, derived from combustion.
Severe burn injury affecting more than 15-20% of the total body area leads to tremendous loss of fluid through the burned skin and fluid replacement is an extremely important form of therapy for these patients. Both crystalloids and colloids are routinely used. Lung injury caused by smoke inhalation and other toxic fumes is also treated with fluids since the injury to the lung also causes loss of fluid.
The critical period of initial resuscitation, i.e. when fluid is administered, is the time when reperfusion injury occurs. During this period, which may be as short as a minute or as long as several hours, oxygen radical mediated injury appears to occur. Presently used volume ejφanders (crystalloids and colloids) do not provide the anti-oxidant properties necessary to mitigate such injury.
Deferoxamine (or desferrioxamine) and its pharmaceutically- acceptable salts are chelating agents. Deferoxamine mesylate is commercially available and is used to treat severe iron intoxication, iron storage disease or iron overload resulting from hemolysis due to drugs, thalassemia, sickle-cell anemia, frequent blood transfusions and the like.
There are a number of problems with the clinical use of deferoxamine mesylate. Since the drug is not appreciably absorbed when orally administered, it generally must be given parenterally. Once administered, the drug is very rapidly excreted. For example, in humans the drug exhibits a vascular half-life of only about 5-10 min. Chelation therapy with the drug, as a result, involves continuous infusion or frequent intramuscular injections, which may cause pain and/or induration at the injection site. Further, the acute and chronic toxicities of deferoxamine are relatively high, making the substance less versatile for therapeutic uses.
The substance deferoxamine is often abbreviated DFO or DES (not to be confused with diethylstilbesterol) . For consistency, only the abbreviation DFO will be used herein. Terms such as "Dextran-DPO" mean an adduct of the polymer (dextran) with DFO. Such an adduct may include more than one DFO moiety per unit substrate.
EP-0 304 183A (corresponding to U.S. patent no. 4 863 964) discloses pharmaceutically acceptable water-soluble biopolymers covalently bonded to deferoxamine. Such biopolymers covalently bonded to deferoxamine are herein referred to as conjugates. Preferred conjugates consist of pharmaceutically acceptable water-soluble polysaccharides covalently bonded to deferoxamine, pharmaceutically acceptable water-soluble proteins covalently bonded to deferoxamine and water-soluble inulm-deferoxamine adducts. It has now been discovered that such conjugates of deferoxamine are useful in fluid resuscitation.
It has also been discovered that DPO and water-soluble biopolymers even if not covalently bonded together may be useful in fluid resuscitation.
Summary of the Invention
The present invention relates to the use of a pharmaceutically acceptable water-soluble biopolymer and deferoxamine (DFO) for use in fluid resuscitation.
In particular the invention relates to the use of such biopolymer and DFO for the preparation or manufacture of a medicament for use in fluid resuscitation.
The biopolymer may be covalently bonded to the DFO. Conjugation of DFO as described above decreases the toxicity of the DFO whilst not reducing or not proportionally reducing its chelating ability.
However, we have some indications that in certain circumstances, free DFO is not as toxic as co πronly asserted.
Accordingly it is within the scope of the invention to use the DFO and the biopolymer in combination with each other as described above but not covalently bound or otherwise conjugated together.
The biopolymer may be a polysaccharide or a protein.
Where the biopolymer is a polysaccharide, the DPO may be covalently bonded directly to aldehydde groups on the polysaccharide.
Where the biopolymer is a protein, the DFO may be covalently bonded directly to one or more amino, carboxyl or thiol groups on the protein. The polysaccharide may comprise dextran, hyaluronic acid, inulin, starch, e.g. hydroxyethyl starch or other modified form of starch.
The protein may coπprise serum albumin or other plasma protein fraction (human or animal) or hemoglobin.
It is envisaged that hemoglobin may be used in resuscitation fluids. Such fluids will provide oxygen to ischemic tissue but may be toxic due to release of iron from the iron-containing protein. The presence of DPO, either bound to or mixed with the hemoglobin may decrease such toxicity.
The DFO-conjugate may be prepared by method as described in EP-E- 0 304 183A.
DPO and the biopolymer, whether or not conjugated together, are preferably formulated as an aqueous solution suitable for parenteral administration e.g. by intramuscular, intraperitoneal or intravenous infusion.
The conjugates between, and the simple mixtures of, polysaccharides and DPO preferably contain from 5 to 25% chelator by weight. It is preferred that -solutions having conjugate corκ_*entrations between 2 and 10% (w/v) , dissolved in saline or lactated Ringer's solution, are used for fluid resuscitation. Effective doses are generally in the range of from approximately 20 to 300 mg chelator/kg body weight, although higher doses of conjugated DPO can be given in certain circumstances, for example in the treatment of acute iron poisoning. Care should be taken when administering the chelator in a form not conjugated to the colloid, since adverse reactions can occur even at moderate doses. - 4A -
Fluid resuscitation using the biopolymer and the DPO ameliorates systemic oxidant injury occurring during ischemia and subsequent reperf sion.
The fluid resuscitation may be indicated in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances, such as smoke, derived from combustion, - hemorrhagic shock and other types of trauma.
Oxygen derived radicals, such as the hydroxyl radical, are cytotoxic and highly reactive molecules are thought to contribute to cellular death in hemorrhagic and thermal shock. Production of hydroxyl radical is catalyzed by transition metal ions. Chelation of transition metal ions with DPO prevents formation of hydroxyl radicals.
By using the DFO and biopolymer according to the present invention
two goals are achieved. Firstly critical volume is provided and, secondly reperfusion injury is prevented or at least attenuated, by removing the iron that catalyzes the reactions leading to formation of oxygen and lipid radicals. This represents a major advance for treating shock and trauma, at the site of an accident, during transport to, and in the hospital.
The need for volume replacement following major thermal injury is less acute than in the case of hemorrhagic shock. However, large volumes are often used and the fluid therapy must be continued for several days. The events occuring in the damaged microvasculature during and following burn injury cannot be clas ified as an example of ischemia followed by reperfusion. However, it has been proposed that the "leaky" microvasculature observed following burn in the injured tissue, and the functional impairment of distal organs (heart, lung and liver), is in part due to o vgen radicals. Treatment with the DFO and biopolymer according to the present invention result, in decreased volume demand (=less leaky microvasculature) and iirproved function of distal organs (---improved cardiac output, lung function and liver blood flow).
The invention is illustrated by the following examples.
Example 1 - Treatment of burn injury
MODEL
Twentythree adult sheep, weighing 40-50kg, were studied. Sheep were prepared with chronic soft tissue lymph fistulas and vascular catheters. Vascular catheters included a swan ganz catheter, carotid arterial line, and jugular venous line. Animals were allowed to recuperate for at least 3 days after the surgical procedure.
BURN INJURY
After a 2 hour ar.es hesia baseline period, a 0-_ r.irά i- r oocy - -
burn was produced under halothane nitrous anesthesia. The burn involved bilateral prefemoral areas over the distribution of bilateral flanks. Resuscitation was begun immediately post burn. The animals were then monitored for 6 hours, then sacrificed. Three groups of animals were studied.
Group 1 Ringers alone as resuscitation fluid; Group 2 5% hydroxyethyl starch alone as resuscitation fluid; Group 3 5% deferoxamine chelator attached i.e. (covalently bonded) to hydroxyethyl starch alone as recuscitation fluid.
PHYSIOLOGIC MEASUREMENTS
Aortic, . central venous, pulmonary arterial, and pulmonary wedge pressures as well as cardiac output were recorded. Hourly values for arterial and venous blood gases as well as' co-oximetry were measured. Co-oximetry measurements include total hemoglobin, reduced hemoglobin, oxygen content, oxygen saturation, and oxygen capacity. Dynamic and static lung compliance was also measured. Urine output and specific gravity were recorded.
BIOCHEMICAL MEASUREMENTS
Malondialdehyde (MDA), a measure of lipid peroxidation, was measured in both lung and liver tissue.
RESULTS
1) Group 3, receiving iron chelator atached to hydroxyethyl starch, required significantly less fluid to maintain hemodynamic stability than either of the other two groups.
The lipid peroxidation level of Group 2 in both lung and liver tissue was within normal levels compared to marked increases in the other groups. - -
MDA nMol/g tissue
n = number of sheep in group.
3) Urine hemolysis seen with burn injury was abolished in Group 3.
4) In the acute-resuscitation period following burn injury (1-2 hrs), an increase in oxygen consumption was noted with the desferal colloid solution, as compared to the Ringers and colloid groups that either had a decrease or no change from controls.
These results show normal levels of lipid peroxidation and greater hemodynamic stability with less fluid volume required. Animals treated with the colloid-chelator conjugate (i.e. the DPO covalently bonded to hydroxyethyl starch) had improved perfusion and blood flow distribution as evidenced by an increase in oxygen consumption.
Example 2 - Treatment of Hemorrhagic Shock
MODEL
A porcine hemorrhagic shock model was used to evaluate the effects of 3 resuscitative fluids on survival and hepatic function. Fasted swine (14-16 kg) underwent splenectomy and placement cf arterial - 8 -
and venous catheters.
INJURY
Awake animals were then bled at lml/kg/min to a mean pressure of 40 mmHg, maintained for 1 hour, and resuscitated over 30 rnins. with 1 of 3 fluids: LR - (n=4) at 3 ml/ml shed blood; PS/LR - 5% PS in LR (n=5) at 1 ml/ml shed blood; DFO-PS/LR- 5% PS with 7.5 mg DPO/ml (n=6) at 1 ml/ml shed blood.
RESULTS
There were no significant differences between groups in MAP, HR, CVP, T or Hct at baseline or after resuscitatiion. LR treated animals all survived less than 2.5 hrs, after resuscitation, whereas PS/LR and DFO-PS/LR survived to sacrifice at 24 hours (P 0.01). AST levels (IU/L) showed no significant difference pre-op and post-resuscitation, but were elevated for PS/LR vs. DFO-PS/LR (338 +/- 161 vs. 106 +/- 57, p 0.03. Colloid resuscitation significantly prolonged survival in this hemorrhage model. This data suggests that DPO conjugate may preserve hepatocyte or microvascular integrity in hemorrhagic shock. Animals treated with the DFO-conjugate seem to have better perfusion of injured tissue, based on hermodynamic variables, than those receiving conventional fluid resuscitation with colloid alone or crystalloid.
Abbreviations used above in this example have the following meanings:
LR lactated Ringers
PS pentastarch (a form of hydroxyethyl starch)
DFO-PS DFO/PS conjugate
AST aspartate amino transferase

Claims

1. A method of fluid resuscitation of the human or animal body, comprising adninistering deferoxamine (DPO) and a water-soluble biopolymer.
2. A method according to claim 1, wherein the DPO and biopolymer are covalently bonded together.
3. A method according to any preceding claim, wherein the biopolymer is a polysaccharide.
4. A method according to claim 3, wherein the DPO is covalently bonded directly to one or more aldehyde on the polysaccharide.
5. A method according to any of claim 3 or 4, wherein the polysaccharide is dextran, hyaluronic acid, inulin or a starch.
6. A method according to claim 1 or 2, wherein the biopolymer is a protein.
7. A method according to claim 6, wherein the DFO is covalently bonded directly to one or more amino, carboxyl or thiol groups on the protein.
8. A method according to claim 6 or 7, wherein the protein is a plasma protein fraction or hemoglobin.
9. A method according to any preceding claim, wherein the DFO and biopolymer are formulated as an aqueous solution suitable for parenteral administration.
10. A method according to any preceding claim, wherein the fluid resuscitation is effected for ameliorating systemic oxidant injury occurring during ischemia and subsequent reperfusion.
11. A method according to any preceding claim, wherein the fluid resuscitation is coπprised in treatment of burn injury, lung injury caused by inhalation of hot and/or toxic substances or heπorrhagic shock.
12. A method according to any preceding claim except claims 2, 4 and 7, wherein the DFO and the biopolymer are not covalently bound or otherwise conjugated together.
13. Use of deferoxamine .and deferoxamine (DPO) and a water-soluble biopolymer for the preparation or manufacture of a medicament for use in fluid resuscitation.
14. Use according to claim 13, wherein the DFO and biopolymer are as specified in any of claims 2 to 9 and 12.
15. Use according to claim 13 or 14, wherein the fluid resuscitation is as specified in claim 10 or 11.
16. A medicament comprising deferoxamine and a water-soluble biopolymer, for use in fluid resuscitation.
17. A medicament according to claim 16, wherein the DFO and the
0 biopolymer are as specified in any of claims 2 to 9 and 12.
18. A medicament according to claim 16 or 17, wherein the fluid resuscitation is as specified in claim 10 or 11.
EP19900907852 1990-03-30 1990-03-30 Fluid resuscitation Withdrawn EP0523037A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002084073A CA2084073A1 (en) 1990-03-30 1990-03-30 Fluid resuscitation
PCT/US1990/001768 WO1991015215A1 (en) 1990-03-30 1990-03-30 Fluid resuscitation

Publications (2)

Publication Number Publication Date
EP0523037A1 EP0523037A1 (en) 1993-01-20
EP0523037A4 true EP0523037A4 (en) 1993-07-28

Family

ID=25675695

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900907852 Withdrawn EP0523037A4 (en) 1990-03-30 1990-03-30 Fluid resuscitation

Country Status (2)

Country Link
EP (1) EP0523037A4 (en)
WO (1) WO1991015215A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
KR100267604B1 (en) * 1993-06-04 2000-11-01 이 세갈 폴 Plasma-like solution
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
DE10222561B4 (en) 2002-05-17 2009-12-10 Dr. Franz Köhler Chemie GmbH Protective solution for the prevention of ischemic damage
EP2442641A4 (en) * 2009-06-16 2016-03-09 Univ Columbia Methods for ameliorating adverse effects associated with transfusion of aged red blood cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900780A (en) * 1988-05-25 1990-02-13 Masonic Medical Research Laboratory Acellular resuscitative fluid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684482A (en) * 1984-01-26 1987-08-04 Oral-D (L.P.) Orally effective ion chelators
US4863964A (en) * 1985-07-02 1989-09-05 Biomedical Frontiers, Inc. Method for the stabilization of deferoxamine to chelate free ions in physiological fluid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900780A (en) * 1988-05-25 1990-02-13 Masonic Medical Research Laboratory Acellular resuscitative fluid

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of WO9115215A1 *
STN FILE SERVER & FILE BIOSIS (KARLSRUHE) 'BA86:127737' *
STN FILE SERVER & FILE BIOSIS (KARLSRUHE) 'BA89:41083' *
STN FILE SERVER & FILE BIOSIS (KARLSRUHE) 'BR38:88128' *

Also Published As

Publication number Publication date
WO1991015215A1 (en) 1991-10-17
EP0523037A1 (en) 1993-01-20

Similar Documents

Publication Publication Date Title
James Methodology for the control of intracranial pressure with hypertonic mannitol
JP5242877B2 (en) Administration of thiol-based chemical protectants
Ahrns Trends in burn resuscitation: shifting the focus from fluids to adequate endpoint monitoring, edema control, and adjuvant therapies
Matsuda et al. Reduced fluid volume requirement for resuscitation of third-degree burns with high-dose vitamin C
KR0156597B1 (en) Method and composition for ameliorating tissue damage due to ischemia and reperfusion
JPS6259222A (en) Method of lowering fibrinolysis and solution therefor
JPH09500366A (en) Methods for improving the therapeutic efficacy of drugs for the treatment of solid tumors and other diseases
Sheridan et al. Low-dose inhaled nitric oxide in acutely burned children with profound respiratory failure
BRPI0621528A2 (en) pharmaceutical composition containing lactate and calcium, and uses thereof
Sigurdsson Intensive care management of acute pancreatitis
US5416078A (en) Fluid resuscitation
EP0523037A4 (en) Fluid resuscitation
Weatherall The pharmacological actions of some contrast media and a comparison of their merits
JPS61502821A (en) drug kit or drug composition
KR102008826B1 (en) Pharmaceutical composition for inhibiting platelet aggregation or for thrombolysis comprising nattokinase and anti-inflammatory agents
POLICE et al. Pulmonary complications after Fluosol administration to patients with life-threatening blood loss
AU654652B2 (en) Fluid resuscitation
JP2000026300A (en) Pharmaceutical composition for protecting vascular endothelial cell
Russell Jr et al. An evaluation of infusion therapy (including dextran) for venous thrombosis
Fine et al. Traumatic shock. VIII. Studies in the therapy and hemodynamics of tourniquet shock
Seltzer et al. Decrease in arterial pressure following heparin injection prior to cardiopulmonary bypass
JPH11514326A (en) Liquid resuscitation medicine
Lauret et al. Vegetating iodides after an intravenous pyelogram
Pascual et al. Blood pressure after three different forms of correction of anemia in hemodialysis
Dundee et al. Effect of thiopentone on blood sugar and glucose tolerance

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921028

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930609

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

DA4 Supplementary search report drawn up and despatched (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 19940117

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 19940118

17Q First examination report despatched

Effective date: 19940727

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990427